Crossref
Governing aging rate indicators from clinical trials to clinical use
Frontiers · 16.09.2026
DOI: 10.25453/plabs.33854755 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers, erschienen am 16.09.2026. Verfasst von Frontiers Policy Labs.
Abstract (Originalsprache)
Dr Michael S. Ringel, Life Biosciences, USA; Dr Carolyn B. Ringel, Harvard Medical School, USA — Biomarkers of aging can inform drug trials and clinical decisions as supportive evidence while formal validation continues. For a full article, please click here.
Schlagwörter
aging biomarkersclinical trialsclinical translationdrug developmentbiomarker validation
Zitieren
APA
Labs, F. P. (2026). Governing aging rate indicators from clinical trials to clinical use. Frontiers. https://doi.org/10.25453/plabs.33854755
Vancouver
Labs FP. Governing aging rate indicators from clinical trials to clinical use. Frontiers. 2026. doi:10.25453/plabs.33854755
BibTeX
@article{Labs2026,
author = {Labs, Frontiers Policy},
title = {Governing aging rate indicators from clinical trials to clinical use},
journal = {Frontiers},
year = {2026},
doi = {10.25453/plabs.33854755}
}
EUVIMED